Entity

Time filter

Source Type

Brea, CA, United States

Beckman Coulter Inc., is an American company that makes biomedical laboratory instruments. Founded by Caltech professor Arnold O. Beckman in 1935 as National Technical Laboratories to commercialize a pH meter that he had invented, the company eventually grew to employ over 10,000 people, with $2.4 billion in annual sales by 2004. Its current headquarters are in Brea, California. Wikipedia.


Dineen S.S.,Tufts University | Dineen S.S.,Beckman Coulter | McBride S.M.,Tufts University | Sonenshein A.L.,Tufts University
Journal of Bacteriology | Year: 2010

CodY, a global regulatory protein that monitors the nutrient sufficiency of the environment by responding to the intracellular levels of GTP and the branched-chain amino acids, was previously shown to be a potent repressor of toxin gene expression in Clostridium difficile during growth in rich medium. In the intestinal tract, such derepression of toxin synthesis would lead to destruction of epithelial cells and the liberation of potential nutrients for the bacterium. CodY is likely to play an important role in regulating overall cellular physiology as well. In this study, DNA microarray analysis and affinity purification of CodY-DNA complexes were used to identify and distinguish the direct and indirect effects of CodY on global gene transcription. A codY null mutation resulted in >4-fold overexpression of 146 genes (organized in 82 apparent transcription units) and underexpression of 19 genes. In addition to the toxin genes, genes for amino acid biosynthesis, nutrient transport, fermentation pathways, membrane components, and surface proteins were overexpressed in the codY mutant. Genome-wide analysis identified more than 350 CodY binding regions, many of which are likely to correspond to sites of direct CodY-mediated regulation. About 60% of the CodY-repressed transcription units were associated with binding regions. Several of these genes were confirmed to be direct targets of CodY by gel mobility shift and DNase I footprinting assays. Copyright © 2010, American Society for Microbiology. All Rights Reserved. Source


Valid J.-M.,Beckman Coulter
Journal of Medical Biochemistry | Year: 2010

Today's hospital laboratory faces increasing pressure to improve turnaround time (TAT), while being required to handle an increasing number of test requests. At the same time, it must operate ever tighter cost controls. Using LEAN process improvement techniques is an effective way of identifying how to delivering greater efficiency and quality. LEAN focuses on identifying those processes that add value and on eliminating the 'waste' - those unnecessary, non value adding steps that cause bottlenecks and delay the delivery of results. Greater use of LEAN analysis also confirms that one of the most effective ways of achieving greater overall efficiency is by automating laboratory processes. With Beckman Coulter's progressive automation solution, a laboratory is likely to see a return on its investment within 18 to 36 months. Beckman Coulter uses a LEAN scorecard to enable the laboratory to easily assess its current testing processes and identify specific areas where improvement is needed. By doing this in advance, a laboratory can expect the implementation of its progressive automation solution to go smoothly. In addition, the average laboratory can automate its pre-analytic testing, using a high speed automated sorter, in as little as two weeks. Source


Alunni-Fabbroni M.,Beckman Coulter | Sandri M.T.,Italian National Cancer Institute
Methods | Year: 2010

Circulating Tumour Cells (CTCs) can be released from the primary tumour into the bloodstream and may colonize distant organs giving rise to metastasis. The presence of CTCs in the blood has been documented more than a century ago, and in the meanwhile various methods have been described for their detection. Most of them require an initial enrichment step, since CTCs are a very rare event. The different technologies and also the differences among the screened populations make the clinical significance of CTCs detection difficult to interprete. Here we will review the different assays up to now available for CTC detection and analysis. Moreover, we will focus on the relevance of the clinical data, generated so far and based on the CTCs analysis. Since the vast majority of data have been produced in breast cancer patients, the review will focus especially on this malignancy. © 2010 Elsevier Inc. All rights reserved. Source


Patent
Beckman Coulter | Date: 2010-03-24

An analyzer includes, as a cleaning system, a cleanser tank that contains a cleanser; a cleaning-water tank that contains cleaning water; a connection pipe that connects the cleanser tank with the cleaning-water tank; a pump that is provided to the connection pipe and pumps the cleanser out of the cleanser tank to the cleaning-water tank; a valve that is provided to the connection pipe and adjusts a flow of the cleanser from the cleanser tank into the cleaning-water tank; and a control unit that opens the valve and causes the pump to pump the cleanser out of the cleanser tank to the cleaning-water tank via the connection pipe to clean the inside of the cleaning-water tank and the insides of cleaning-water flow-path constituents that form a flow path through which the cleaning water flows from the cleaning-water tank when the specimen is subjected to an analysis process.


Patent
Beckman Coulter | Date: 2015-08-26

A diagnostic instrument is disclosed. The diagnostic instrument may have a highly efficient probe washer station and/or may be able to sense whether there is a tube septum on a specimen tube to be sampled. The instrument may also be able to determine where the bottom of the tube is located. The probe washer station may have a flow of saline that is used to wash both the internal cavity and the external circumference of the probe.

Discover hidden collaborations